Single Dose PG102 in Patients With Active Psoriatic Arthritis

计划入组 17 人 · 首次发布于 2008 年 11 月 7 日

A Study of Picankibart in Patients With Active Psoriatic Arthritis

计划入组 222 人 · 首次发布于 2025 年 12 月 19 日

A Study of Guselkumab in Participants With Active Psoriatic Arthritis

计划入组 1,054 人 · 首次发布于 2021 年 5 月 11 日

Certolizumab pegol(Cimzia)

Upadacitinib(Rinvoq)

C₁₇H₁₉F₃N₆O · Rx

membrane-active bakuchiol

CARE Arthritis Ltd

Canada

Arthritis Innovation Corporation

Canada

COSMETIQUE ACTIVE PRODUCTION

France

TREMFYA Becomes First IL-23 Inhibitor to Reduce Structural Damage in Psoriatic Arthritis

Sun Pharma's ILUMYA Achieves Primary Endpoints in Two Phase 3 Psoriatic Arthritis Trials

FDA Approves Single-Injection 320 mg BIMZELX® for Plaque Psoriasis and Psoriatic Arthritis